We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+17.66%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$238M
AUM Growth
+$15.3M
Cap. Flow
+$15.4M
Cap. Flow %
6.48%
Top 10 Hldgs %
90.75%
Holding
25
New
6
Increased
7
Reduced
5
Closed
6

Top Buys

1
THRD
Third Harmonic Bio
THRD
+$33.7M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$8.2M
3
APEN
Apollo Endosurgery, Inc.
APEN
+$6.67M
4
ADMA icon
ADMA Biologics
ADMA
+$5.98M
5
EOLS icon
Evolus
EOLS
+$4.91M

Top Sells

1
QDEL icon
QuidelOrtho
QDEL
+$17.1M
2
AMRN
Amarin Corp
AMRN
+$9.32M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$8.57M
4
AFMD
Affimed
AFMD
+$4.08M
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.01M

Sector Composition

1 Healthcare 98.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$46.2M 19.45%
6,333,239
+105,506
+2% +$744K
APEN
2
DELISTED
Apollo Endosurgery, Inc.
APEN
$37.2M 15.63%
3,726,584
+893,953
+32% +$6.67M
CTIC
3
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$29.7M 12.47%
4,934,100
-735,288
-13% -$4.01M
ADMA icon
4
ADMA Biologics
ADMA
$2.02B
$26.9M 11.33%
6,940,000
+1,940,000
+39% +$5.98M
QDEL icon
5
QuidelOrtho
QDEL
$1.19B
$25.7M 10.81%
300,000
-201,633
-40% -$17.1M
XERS icon
6
Xeris Biopharma Holdings
XERS
$1.52B
$14.9M 6.26%
11,195,189
-1,732,979
-13% -$2.45M
URGN icon
7
UroGen Pharma
URGN
$1.96B
$11.6M 4.87%
1,304,947
+180,727
+16% +$1.71M
THRD
8
DELISTED
Third Harmonic Bio
THRD
$8.67M 3.65%
+2,015,301
New +$33.7M
LKFT
9
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$8.65M 3.64%
+194,836
New +$8.2M
EOLS icon
10
Evolus
EOLS
$377M
$6.27M 2.64%
834,432
+634,432
+317% +$4.91M
RZLT icon
11
Rezolute
RZLT
$444M
$6.25M 2.63%
3,021,504
+48,299
+2% +$90.4K
CSTL icon
12
Castle Biosciences
CSTL
$733M
$4.2M 1.77%
+178,240
New +$4.13M
CFMS
13
DELISTED
Conformis, Inc. Common Stock
CFMS
$2.48M 1.05%
748,194
+56,020
+8% +$174K
MIRM icon
14
Mirum Pharmaceuticals
MIRM
$7.25B
$2.12M 0.89%
+108,769
New +$2.15M
XGN icon
15
Exagen
XGN
$106M
$2.05M 0.86%
854,042
-411,331
-33% -$1.06M
MXCT icon
16
MaxCyte
MXCT
$133M
$1.49M 0.63%
+273,287
New +$1.68M
OABI icon
17
OmniAb
OABI
$307M
$1.28M 0.54%
+354,266
New +$1.86M
XOMA
18
DELISTED
Xoma
XOMA
$1.19M 0.5%
64,459
– –
OPTN
19
DELISTED
OptiNose
OPTN
$940K 0.4%
33,886
-99,447
-75% -$3.78M
AFMD
20
DELISTED
Affimed
AFMD
– –
-197,983
Closed -$4.08M
AMRN
21
Amarin Corp
AMRN
$292M
– –
-427,398
Closed -$9.32M
LGND icon
22
Ligand Pharmaceuticals
LGND
$6.08B
– –
-159,598
Closed -$8.57M
OVID icon
23
Ovid Therapeutics
OVID
$455M
– –
-1,540,671
Closed -$2.83M
ATYR
24
aTyr Pharma
ATYR
$50M
– –
-600,980
Closed -$1.8M
OPNT
25
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
– –
-152,278
Closed -$1.64M

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Stonepine Capital Management held 25 positions worth $238M, up 6.9% from $222M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Stonepine Capital Management deployed $15.4M of net new capital in Q4 2022, opening 6 new positions and adding to 7 existing holdings. Its largest new stake was Third Harmonic Bio: 2,015,301 shares worth $8.67M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was QuidelOrtho, an estimated $17.1M trimmed.

  • Stonepine Capital Management's largest Q4 2022 buy was Third Harmonic Bio: 2,015,301 shares worth $8.67M.
  • Stonepine Capital Management added most to Apollo Endosurgery, Inc. in Q4 2022, an estimated $6.67M increase.
  • Stonepine Capital Management's biggest Q4 2022 reduction was QuidelOrtho, cutting an estimated $17.1M.
  • Stonepine Capital Management fully exited Amarin Corp in Q4 2022, selling an estimated $9.32M.
  • Stonepine Capital Management's ten largest holdings make up 91% of its $238M portfolio in Q4 2022.
  • Stonepine Capital Management opened 6 new positions and closed 6 in Q4 2022.
  • Stonepine Capital Management's portfolio value rose 6.9% quarter-over-quarter to $238M.

Based on Stonepine Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.